Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, immunotherapies, and biomarker-driven treatment approaches is further reshaping the treatment landscape. Additionally, the launch of emerging therapies such as RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), and others will further propel the market growth.

New York, USA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

 The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, immunotherapies, and biomarker-driven treatment approaches is further reshaping the treatment landscape. Additionally, the launch of emerging therapies such as RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), and others will further propel the market growth.

Recently published Colorectal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, colorectal cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Colorectal Cancer Market Summary

• The total market size of mCRC in the 7MM in 2025 was approximately USD 13 billion, and this is anticipated to grow by 2036.
• The United States accounted for the largest colorectal cancer treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, total incident cases of colorectal cancer in the 7MM were ~555K.
• Key colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Exelixis, Agenus, Verastem Oncology, Adagene, Summit Therapeutics, AbbVie, Oncolytics Biotech, Sanofi, Revolution Medicines, Frontier Medicines, Jacobio Pharmaceuticals, and others, are actively working on innovative colorectal cancer drugs. 
• Some of the key colorectal cancer therapies in clinical trials include RYBREVANT (amivantamab) + Chemotherapy, Serplulimab (HLX10) + HLX04 + Chemotherapy, Zanzalintinib (XL092), Botensilimab + balstilimab (BOT/BAL), VS-7375, Muzastotug (ADG126), Ivonescimab, Temab-A (ABBV-400), Pelareorep, SAR445953, Elironrasib (RMC-6291), FMC-376, Glecirasib (JAB-21822), and others. These novel colorectal cancer therapies are anticipated to enter the colorectal cancer market in the forecast period and are expected to change the market.

Discover the future of the colorectal cancer therapeutics market @ https://www.delveinsight.com/report-store/colorectal-cancer-crc-market

Key Factors Driving the Growth of the Colorectal Cancer Market 

• Rising Incidence of Colorectal Cancer: The growing global burden of colorectal cancer, driven by aging populations, sedentary lifestyles, obesity, and dietary risk factors, is increasing demand for screening, diagnosis, and treatment. 
• Advancements in Targeted Therapies: Increasing development and adoption of targeted therapies, including EGFR, VEGF, BRAF, and HER2-directed treatments, are broadening therapeutic options for patients with specific molecular profiles. These therapies are also supporting the shift toward more personalized colorectal cancer treatment.
• Expansion of Immunotherapy: Immune checkpoint inhibitors have introduced new treatment options, particularly for patients with MSI-high or mismatch repair-deficient colorectal cancer. Continued clinical research into immunotherapies and combination regimens is expected to strengthen their role across different stages of the disease.
• Improved Colorectal Cancer Screening: Increased awareness and implementation of screening programs are facilitating earlier detection of colorectal cancer and precancerous lesions. The adoption of colonoscopy, stool-based tests, and other non-invasive screening technologies is contributing to higher diagnosis rates and treatment demand.
• Launch of Emerging Colorectal Cancer Drugs: The dynamics of the CRC market are expected to change in the coming years due to the launch of emerging therapies such as RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), Botensilimab + balstilimab (BOT/BAL; Agenus), VS-7375 (Verastem Oncology), Muzastotug (ADG126; Adagene), and others.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that integration of chemotherapy, radiation, and surgery with modern therapeutic approaches enhances treatment efficacy and presents opportunities for further innovation. 

Colorectal Cancer Market Analysis

• The treatment approach may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, depending on disease characteristics and treatment goals. 
• These modalities can help control disease progression and may temporarily reduce tumor burden. Palliative care also plays an important role in managing disease-related symptoms and treatment-associated adverse effects.
• Fluoropyrimidine (FP)-based therapy forms the foundation of first-line palliative chemotherapy, either as monotherapy or in combination with targeted therapies. 
• Common FP options include intravenous 5-fluorouracil (5-FU) and the oral agent capecitabine, with capecitabine generally considered an alternative to continuous intravenous 5-FU/leucovorin (LV). 
• Combination regimens such as 5-FU/LV plus oxaliplatin (FOLFOX) or 5-FU/LV plus irinotecan (FOLFIRI) have demonstrated higher response rates (RRs), longer progression-free survival (PFS), and improved overall survival compared with 5-FU/LV alone. 
• For patients who progress or are refractory to FOLFOX or CAPEOX, irinotecan-based regimens are commonly used in the second-line setting, including irinotecan monotherapy and FOLFIRI. 
• Evidence indicates that FOLFIRI may offer a more favorable therapeutic index than irinotecan alone in the second-line setting, with safety advantages associated with the combination regimen.
• Several therapies are currently under development for colorectal cancer, including RYBREVANT (amivantamab) in combination with chemotherapy (Johnson & Johnson Innovative Medicine), serplulimab (HLX10) plus HLX04 and chemotherapy (Shanghai Henlius Biotech), zanzalintinib (XL092; Exelixis), botensilimab plus balstilimab (BOT/BAL; Agenus), VS-7375 (Verastem Oncology), and other emerging candidates.
• Overall, the CRC treatment landscape is expected to undergo substantial evolution as emerging therapies enter the market and address persistent unmet medical needs. These novel agents have the potential to improve patient outcomes through more targeted and personalized treatment strategies, enhanced efficacy in refractory disease, and broader therapeutic options beyond conventional chemotherapy. 
• With the increasing adoption of biomarker-driven therapies and immunotherapy-based combinations, the CRC market is likely to become more competitive, while expanding treatment choices may contribute to improved disease control, survival, and quality of life.

Learn more about the colorectal cancer screening market @ Colorectal Cancer Medication

Colorectal Cancer Competitive Landscape

Some of the colorectal cancer drugs under development include RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), Botensilimab + balstilimab (BOT/BAL; Agenus), VS-7375 (Verastem Oncology), Muzastotug (ADG126; Adagene), Ivonescimab (Summit Therapeutics), Temab-A (ABBV-400; AbbVie), Pelareorep (Oncolytics Biotech), SAR445953 (Sanofi), Elironrasib (RMC-6291; Revolution Medicines), FMC-376 (Frontier Medicines), Glecirasib (JAB-21822; Jacobio Pharmaceuticals), and others.

Johnson & Johnson Innovative Medicine’s Amivantamab is a bispecific antibody designed to target specific genetic alterations, particularly EGFR exon 20 insertion mutations. Its mechanism of action involves dual targeting of the epidermal growth factor receptor (EGFR) and the MET receptor, both of which play important roles in tumor growth, proliferation, and survival. By binding to these receptors, amivantamab inhibits their downstream signaling pathways and may help overcome certain resistance mechanisms that tumors develop in response to other targeted therapies. The drug is currently in Phase III clinical development for the treatment of metastatic colorectal cancer (mCRC).

Shanghai Henlius Biotech’s HLX10 is a novel recombinant humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), independently developed by Henlius. HLX04 is a bevacizumab biosimilar independently developed by Henlius in accordance with the Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative). It is indicated for the treatment of advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

AbbVie’s ABBV-400 is an investigational antibody-drug conjugate (ADC) developed by AbbVie that targets c-Met, a receptor tyrosine kinase frequently overexpressed in several cancers, including colorectal cancer (CRC). By selectively targeting c-Met-expressing tumor cells, ABBV-400 is designed to deliver its cytotoxic payload to cancer cells. The drug is currently in Phase III clinical development for the treatment of mCRC.

The anticipated launch of these emerging colorectal cancer therapies are poised to transform the colorectal cancer market landscape in the coming years. As these cutting-edge colorectal cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the colorectal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about the colorectal cancer diagnostics and therapeutic market, visit @ Drug for Colorectal Cancer 

Recent Developments in the Colorectal Cancer Market

• In September 2026, Oncolytics Biotech® Inc. announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep as a second-line treatment for patients with RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer.
• In September 2026 SEC filing, Exelixis announced that the FDA had extended its review of zanzalintinib by three months, with the new target action date set for March 3, 2027.
• In August 2026, Innovent dosed the first patient in a pivotal China study evaluating IBI363 (TAK-928) in combination with bevacizumab for late-line advanced colorectal cancer. 
• In June 2026, Exelixis, Inc. announced findings from the final analysis of the dual primary endpoint of overall survival (OS) among patients without active liver metastases (non-liver metastases, NLM) in the Phase 3 STELLAR-303 pivotal trial. 

Colorectal Cancer Epidemiology Segmentation

The colorectal cancer epidemiology section provides insights into the historical and current colorectal cancer patient pool and forecasted trends for the leading markets. United States accounted for the highest number of mCRC cases in the 7MM, around 25% in 2025.

The colorectal cancer market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

• Total Incident Cases of CRC
• Gender-specific Cases of CRC
• Age-specific Cases of CRC
• Tumor Localization-specific Cases of CRC
• Stage-specific Cases of CRC
• Mutation-specific Cases of CRC
• Total Treated Cases of CRC by Line of Therapies

Download the report to understand the new colorectal cancer treatments @ Colorectal Cancer Drugs

Scope of the Colorectal Cancer Market Report

• Colorectal Cancer Patient Population Forecast
• Colorectal Cancer Therapeutics Market Size
• Colorectal Cancer Pipeline Analysis
• Colorectal Cancer Market Size and Trends
• Colorectal Cancer Market Opportunity
• Colorectal Cancer Market Unmet Needs
• KOL’s Views on Colorectal Cancer
• Colorectal Cancer Market Access and Reimbursement

Discover more about next-generation colorectal cancer drugs @ Colorectal Cancer Clinical Trials

Table of Contents

Related Reports

KRAS Inhibitors Market 

KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Roche, Chugai, Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, Astex Pharmaceuticals, Cardiff Oncology, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Genfleet Therapeutics, Innovent, Jacobio Pharma, Tyligand Pharmaceuticals (Suzhou), Silexion Therapeutics, Catalent, Astellas Pharma, Incyte, Pfizer, Bayer, Kumquat Biosciences, Quanta Therapeutics, and others.

Colorectal Cancer Clinical Trial Analysis 

Colorectal Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key colorectal cancer companies, including Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE,  and others.

Metastatic Colorectal Cancer Market

Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, and others.

Metastatic Colorectal Cancer Clinical Trial Analysis 

Metastatic Colorectal Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal cancer companies, including Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Exelixis, Daiichi Sankyo, Hutchmed, Merus N.V., REVOLUTION Medicines, Pure Tech Health, Medicenna Therapeutics, Inc., Verastem Inc., Next Cure Inc., Isofol Medical, Zentalis Pharmaceuticals, Oncoinvent, KaryoPharm Therapeutics, Aadi Biosciences,  and others.

Microsatellite Stable Colorectal Cancer Market

Microsatellite Stable Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key microsatellite stable colorectal cancer companies, including Roche, Bristol Myers Squibb, Merck & Co., Amgen, BeiGene, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679